Q-omics provides the consensus-scored HNRNPA3P16 profile across patient tissues and cancer cell-line models. HNRNPA3P16 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, HNRNPA3P16 is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, HNRNPA3P16 RNA expression shows 6,712 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, and STAD as cancer lineages where HNRNPA3P16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPA3P16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPA3P16 survival associations across molecular data types. HNRNPA3P16 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPA3P16 RNA expression–survival associations across cancer types. High HNRNPA3P16 expression shows unfavorable associations in THCA, BLCA, READ, ACC and KIRC, but favorable associations in MESO. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for HNRNPA3P16 RNA expression.
This table summarizes HNRNPA3P16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for HNRNPA3P16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPA3P16 shows lower tumor expression in THCA and KIRC. The THCA box plot shows higher HNRNPA3P16 RNA expression in normal versus tumor tissue (log2 FC = −0.051, t-test p = .003).
This table shows molecular features associated with HNRNPA3P16 in patient tissues and cancer cell lines. In patient samples, HNRNPA3P16 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
